Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be performed on all subjects. The eligible subject population consists of subjects who have been diagnosed with locally advanced or metastatic melanoma that is refractory to standard therapy or for which no curative standard therapy exists.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Confirmed diagnosis of locally advanced or metastatic melanoma (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC or IV) that is refractory to standard therapy or for which no curative standard therapy exists.
Must be eighteen years of age or older
Must meet baseline laboratory requirements
ECOG performance status 0 or 1
Adults of reproductive potential must agree to use effective contraception or be sterile
Concurrent therapy with any other investigational agent
Uncontrolled central nervous system metastases
Impaired cardiac function or clinically significant cardiac disease
chemotherapy, targeted therapy or monoclonal antibody therapy ≤4 weeks
biological therapy or immunotherapy (therapeutic or diagnostic) ≤2 weeks
an investigational agent (therapeutic or diagnostic) ≤4 weeks prior to starting study drug or has not recovered from side effects of such therapy
Received any hematopoietic colony-stimulating factor (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin is allowed.
Has undergone major surgery ≤ 2 weeks prior to starting study drug or has not recovered from side effects of such surgery.
Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as nausea, diarrhea, vomiting
Pregnant or breast feeding women
History of another primary malignancy that is currently clinically significant or currently requires active intervention.
Chronic anticoagulation therapy with full strength aspirin, Coumadin, or heparin.
History of thromboembolic or cerebrovascular events within the last 12 months.
History of rectal bleeding, bloody vomit, or spitting up blood within the last 3 months.
Known diagnosis of HIV infection (HIV testing is not mandatory)
Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort and quinidine is prohibited.
Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study-drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, make the patient inappropriate for this study